What is Leqvio and How Does It Work?
Leqvio (inclisiran) is a prescription medication designed to lower low-density lipoprotein (LDL) cholesterol, commonly referred to as ‘bad’ cholesterol. It is specifically prescribed for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), an inherited condition that causes high cholesterol levels. This treatment is used in combination with a healthy diet and regular exercise.
The active ingredient in Leqvio is inclisiran. It works by targeting a specific protein in the liver called PCSK9, which normally prevents the body from clearing LDL cholesterol. By reducing the production of this protein, Leqvio helps the liver remove more LDL cholesterol from the bloodstream, effectively lowering overall cholesterol levels.
Leqvio Dosage and Administration
Leqvio is administered as an injection under the skin (subcutaneously) by a healthcare professional. It comes in a single-dose prefilled syringe containing 284 mg of the drug in 1.5 mL of solution.
The standard dosing schedule begins with an initial injection, followed by a second dose three months later. After these first two starter doses, patients receive maintenance injections once every six months. This twice-a-year maintenance schedule makes it a convenient option for long-term cholesterol management.
Potential Side Effects of Leqvio
Like all prescription medications, Leqvio can cause side effects, though they are generally mild. The most common side effects reported include mild injection site reactions, such as pain, redness, or warmth where the injection was given. Other potential mild side effects include joint pain and bronchitis.
Serious side effects are rare but can include severe injection site reactions or allergic reactions. Symptoms of a severe allergic reaction may include difficulty breathing, swelling of the face or throat, and severe rash. Anyone experiencing these symptoms should seek immediate medical attention.
Comparing Leqvio with Other Cholesterol Treatments
While Leqvio works similarly to other cholesterol-lowering drugs known as PCSK9 inhibitors, such as Repatha (evolocumab) or Praluent (alirocumab), it is classified differently and has a distinct dosing schedule. Repatha and Praluent are typically self-injected at home every two to four weeks, whereas Leqvio is administered by a healthcare provider twice a year after the initial doses.
Leqvio is not a statin. However, doctors frequently prescribe Leqvio alongside statins, such as atorvastatin or rosuvastatin, to achieve optimal cholesterol reduction. For patients who cannot tolerate statins, Leqvio may be paired with other cholesterol-lowering medications like ezetimibe.
Important Considerations Before Starting Treatment
Before beginning Leqvio, patients should discuss their complete medical history with their doctor. It is particularly important to disclose any history of severe liver problems, as the drug’s effects in individuals with severe hepatic impairment have not been fully studied.
The safety of Leqvio during pregnancy and breastfeeding remains unknown. Because developing fetuses require cholesterol, cholesterol-lowering medications like Leqvio are generally not recommended for pregnant individuals. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider to explore alternative treatment options.
Leave a Reply